Cortisone_DataSheet_MedChemExpress
牛皮质醇(Cortisol)说明书
牛皮质醇(Cortisol)酶联免疫分析(ELISA)试剂盒使用说明书本试剂仅供研究使用目的：本试剂盒用于测定牛血清，血浆及相关液体样本中皮质醇(Cortisol)的含量。
实验原理：本试剂盒应用双抗体夹心法测定标本中牛皮质醇（Cortisol）水平。
用纯化的牛皮质醇（Cortisol）抗体包被微孔板，制成固相抗体，往包被单抗的微孔中依次加入皮质醇（Cortisol），再与HRP标记的皮质醇（Cortisol）抗体结合，形成抗体-抗原-酶标抗体复合物，经过彻底洗涤后加底物TMB显色。
TMB在HRP酶的催化下转化成蓝色，并在酸的作用下转化成最终的黄色。
颜色的深浅和样品中的皮质醇（Cortisol）呈正相关。
用酶标仪在450nm波长下测定吸光度（OD值），通过标准曲线计算样品中牛皮质醇（Cortisol）浓度。
样本处理及要求：1. 血清：室温血液自然凝固10-20分钟，离心20分钟左右（2000-3000转/分）。
仔细收集上清，保存过程中如出现沉淀，应再次离心。
2. 血浆：应根据标本的要求选择EDTA或柠檬酸钠作为抗凝剂，混合10-20分钟后，离心20分钟左右（2000-3000转/分）。
仔细收集上清，保存过程中如有沉淀形成，应该再次离心。
3. 尿液：用无菌管收集，离心20分钟左右（2000-3000转/分）。
仔细收集上清，保存过程中如有沉淀形成，应再次离心。
胸腹水、脑脊液参照实行。
4. 细胞培养上清：检测分泌性的成份时，用无菌管收集。
离心20分钟左右（2000-3000转/分）。
仔细收集上清。
检测细胞内的成份时，用PBS（PH7.2-7.4）稀释细胞悬液，细胞浓度达到100万/ml左右。
通过反复冻融，以使细胞破坏并放出细胞内成份。
离心20分钟左右（2000-3000转/分）。
仔细收集上清。
保存过程中如有沉淀形成，应再次离心。
5. 组织标本：切割标本后，称取重量。
加入一定量的PBS，PH7.4。
用液氮迅速冷冻保存备用。
兔子皮质醇(Cortisol)酶联免疫分析试剂盒说明书
兔子皮质醇（Cortisol）酶联免疫分析试剂盒使用说明书本试剂盒仅供体外研究使用!预期应用ELISA法定量测定兔子血清、血浆或其它相关生物液体中皮质醇（Cortisol）含量。
实验原理用纯化的抗体包被微孔板，制成固相载体，往包被抗皮质醇（Cortisol）抗体的微孔中依次加入标本或标准品、生物素化的抗皮质醇（Cortisol）抗体、HRP标记的亲和素，经过彻底洗涤后用底物TMB显色。
TMB在过氧化物酶的催化下转化成蓝色，并在酸的作用下转化成最终的黄色。
颜色的深浅和样品中的皮质醇（Cortisol）呈正相关。
用酶标仪在450nm波长下测定吸光度（OD值），计算样品浓度。
试剂盒组成及试剂配制1.酶联板：一块（96孔）2.标准品（冻干品）：2瓶，每瓶临用前以样品稀释液稀释至1ml，盖好后静置10分钟以上，然后反复颠倒/搓动以助溶解，其浓度为180ng/ml，做系列倍比稀释（注：不要直接在板中进行倍比稀释）后，分别稀释成180ng/ml，90ng/ml，45ng/ml，22.5ng/ml，11.25ng/ml，5.63ng/ml，2.82ng/ml，样品稀释液直接作为标准浓度0ng/ml，临用前15分钟内配制。
如配制90ng/ml标准品：取0.5ml（不要少于0.5ml）180ng/ml的上述标准品加入含有0.5ml 样品稀释液的Eppendorf管中，混匀即可，其余浓度以此类推。
3.样品稀释液：1×20ml。
4.检测稀释液A：1×10ml。
5.检测稀释液B：1×10ml。
6.检测溶液A：1×120μl（1:100）临用前以检测稀释液A1:100稀释，稀释前根据预先计算好的每次实验所需的总量配制（100μl/孔），实际配制时应多配制0.1-0.2ml。
如10μl检测溶液A加990μl检测稀释液A的比例配制，轻轻混匀，在使用前一小时内配制。
7.检测溶液B：1×120μl/瓶（1:100）临用前以检测稀释液B1:100稀释。
Cortisol中文说明书
用免疫学方法定量测定人血清或血浆中皮质醇（ｃｏｒｔｉｓｏｌ）的含量。电化学发光免疫测 · Ｅｌｅｃｓｙｓ 系统清洗液支架（Ａｄａｐｔｅｒ ｆｏｒ ＳｙｓＣｌｅａｎ） ）货号１１９３３１５９
定试剂，适用于罗氏Ｅｌｅｃｓｙｓ１０１０、２０１０和Ｅ１７０（Ｅｌｅｃｓｙｓ模块）免疫测定分析仪。 · Ｅｌｅｃｓｙｓ １０１０反应杯（Ａｓｓａｙ Ｃｕｐ） 货号１１７０６８２９
与其它糖皮质类固醇激素一样，皮质醇由共同前体胆固醇在肾上腺皮质区合成而来。 在外周血中，９０％的皮质醇与皮质类固醇结合球蛋白（ＣＢＧ）以及白蛋白结合后进行 运输。 皮质醇最重要的的生理机能是升高血糖，抗炎和免疫抑制作用。 皮质醇的合成和分泌受下丘脑－垂体－肾上腺皮质轴的负反馈机制的调节。当皮质 醇水平下降时，下丘脑分泌促肾上腺皮质激素释放激素（ＣＲＨ），使垂体分泌促肾 上腺皮质激素（ＡＣＴＨ），并由ＡＣＴＨ刺激肾上腺合成并分泌皮质醇。皮质醇本身对垂
Ｅｌｅｃｓｙｓ１０１０／２０１０分析仪需要 · Ｅｌｅｃｓｙｓ系统缓冲液（ＰｒｏＣｅｌｌ）货号１１６６２９８８
机器自动稀释，机器会自动计算结果。 正常参考值：
· Ｅｌｅｃｓｙｓ 测量池清洗液（ＣｌｅａｎＣｅｌｌ）货号１１６６２９７０
上午时间 ７－１０ ａ．ｍ． ： １７１－５３６ ｎｍｏｌ／ｌ （６．２－１９．４μｇ／ｄｌ） （ｎ＝１４４） 下午时间 ４－８ ｐ．ｍ． ： ６４－３４０ ｎｍｏｌ／ｌ （２．３－１２．３μｇ／ｄｌ） （ｎ＝１３７） 如有必要，各实验室应自己测定一个正常值范围。
采取校正措施。 计算： 对每一个标本，仪器会自动计算皮质醇含量，单位是ｎｍｏｌ／ｌ，µg／ｄｌ或µg／ｌ。换算 方法 nmol/l x 0.03625 = µg/dl (x 0.3625 = µg/l)
阿利新蓝染色液(pH=1.0)试剂盒
阿利新蓝染色液(pH=1.0)试剂盒货号：G1563规格：3×50mL/3×100mL保存：4℃，避光，6个月。
产品说明：阿利新蓝（Alcian）又称爱先蓝或阿尔辛蓝等，是一种类铜钛花青共轭染料，最初用于纺织纤维染色。
这种阳离子染料与酸性基团结合，即阿尔辛蓝与组织内含有的阴离子基团如羧基和硫酸根形成不溶性复合物。
阿利新蓝由中央含铜的酞菁环与四个异硫脲基通过硫醚键相连而成。
该异硫脲基呈中度碱性，使阿利新蓝带阳离子。
阿利新蓝使碳水化合物着色的确切机制不明，普遍认为是阳离子的异硫脲基通过静电与组织内的多聚阴离子相连。
如含羧基和硫酸根的酸性黏液物质的羧基和硫酸根形成不溶性复合物，即染料分子中带正电荷的盐键和酸性黏液物质中带负电荷的酸性基团结合呈蓝色。
利用染液的不同pH值可判定粘液物质的类属。
在pH=1时，羧基不能离子化因而不能着染，但硫酸基可以被显示。
在pH=2.5的时候，带羧基的粘液质（如蛋白多糖/透明质酸以及上皮酸性黏蛋白）着色良好而硫酸化粘液质着染不佳。
中性黏液质如胃黏膜和Brunner腺体部位的中性黏蛋白不能与阿利新蓝反应着色。
常用于粘液性上皮肿瘤的鉴别和肿瘤中是否含有粘液物质的证明。
产品组成：名称货号G15633×50mLG15633×100mLStorage试剂(A):Alcian酸化液50mL100mL RT试剂(B):Alcian染色液50mL100mL4℃，避光试剂(C):核固红染色液50mL100mL RT，避光说明书1份操作说明：（仅供参考）1、二甲苯脱蜡，通过梯度乙醇后，入蒸馏水水化。
2、入Alcian染色液浸染30min。
3、流水冲洗。
4、Alcian酸化工作液稍洗(按Alcian酸化液:蒸馏水=1:2的比例配制)。
5、不经水洗，直接用滤纸吸干多余的Alcian酸化工作液。
6、入核固红染色液复染5min。
7、流水冲洗。
8、常规乙醇脱水，二甲苯透明，中性树胶封片。
Calcipotriol_SDS_MedChemExpress
Inhibitors, Agonists, Screening LibrariesSafety Data Sheet Revision Date:Sep.-13-2017Print Date:Sep.-13-20171. PRODUCT AND COMPANY IDENTIFICATION1.1 Product identifierProduct name :CalcipotriolCatalog No. :HY-10001CAS No. :112965-21-61.2 Relevant identified uses of the substance or mixture and uses advised againstIdentified uses :Laboratory chemicals, manufacture of substances.1.3 Details of the supplier of the safety data sheetCompany:MedChemExpress USATel:609-228-6898Fax:609-228-5909E-mail:sales@1.4 Emergency telephone numberEmergency Phone #:609-228-68982. HAZARDS IDENTIFICATION2.1 Classification of the substance or mixtureNot a hazardous substance or mixture.2.2 GHS Label elements, including precautionary statementsNot a hazardous substance or mixture.2.3 Other hazardsNone.3. COMPOSITION/INFORMATION ON INGREDIENTS3.1 SubstancesSynonyms:MC 903; CalcipotrieneFormula:C27H40O3Molecular Weight:412.60CAS No. :112965-21-64. FIRST AID MEASURES4.1 Description of first aid measuresEye contactRemove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelids with fingers to ensure adequate flushing. Promptly call a physician.Skin contactRinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.InhalationImmediately relocate self or casualty to fresh air. If breathing is difficult, give cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouth resuscitation.IngestionWash out mouth with water; Do NOT induce vomiting; call a physician.4.2 Most important symptoms and effects, both acute and delayedThe most important known symptoms and effects are described in the labelling (see section 2.2).4.3 Indication of any immediate medical attention and special treatment neededTreat symptomatically.5. FIRE FIGHTING MEASURES5.1 Extinguishing mediaSuitable extinguishing mediaUse water spray, dry chemical, foam, and carbon dioxide fire extinguisher.5.2 Special hazards arising from the substance or mixtureDuring combustion, may emit irritant fumes.5.3 Advice for firefightersWear self-contained breathing apparatus and protective clothing.6. ACCIDENTAL RELEASE MEASURES6.1 Personal precautions, protective equipment and emergency proceduresUse full personal protective equipment. Avoid breathing vapors, mist, dust or gas. Ensure adequate ventilation. Evacuate personnel to safe areas.Refer to protective measures listed in sections 8.6.2 Environmental precautionsTry to prevent further leakage or spillage. Keep the product away from drains or water courses.6.3 Methods and materials for containment and cleaning upAbsorb solutions with finely-powdered liquid-binding material (diatomite, universal binders); Decontaminate surfaces and equipment by scrubbing with alcohol; Dispose of contaminated material according to Section 13.7. HANDLING AND STORAGE7.1 Precautions for safe handlingAvoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation.7.2 Conditions for safe storage, including any incompatibilitiesKeep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition.Recommended storage temperature: 4°C, protect from light, stored under nitrogenShipping at room temperature if less than 2 weeks.7.3 Specific end use(s)No data available.8. EXPOSURE CONTROLS/PERSONAL PROTECTION8.1 Control parametersComponents with workplace control parametersThis product contains no substances with occupational exposure limit values.8.2 Exposure controlsEngineering controlsEnsure adequate ventilation. Provide accessible safety shower and eye wash station.Personal protective equipmentEye protection Safety goggles with side-shields.Hand protection Protective gloves.Skin and body protection Impervious clothing.Respiratory protection Suitable respirator.Environmental exposure controls Keep the product away from drains, water courses or the soil. Cleanspillages in a safe way as soon as possible.9. PHYSICAL AND CHEMICAL PROPERTIES9.1 Information on basic physical and chemical propertiesAppearance White to off-white (Solid)Odor No data availableOdor threshold No data availablepH No data availableMelting/freezing point No data availableBoiling point/range No data availableFlash point No data availableEvaporation rate No data availableFlammability (solid, gas)No data availableUpper/lower flammability or explosive limits No data availableVapor pressure No data availableVapor density No data availableRelative density No data availableWater Solubility No data availablePartition coefficient No data availableAuto-ignition temperature No data availableDecomposition temperature No data availableViscosity No data availableExplosive properties No data availableOxidizing properties No data available9.2 Other safety informationNo data available.10. STABILITY AND REACTIVITY10.1 ReactivityNo data available.10.2 Chemical stabilityStable under recommended storage conditions.10.3 Possibility of hazardous reactionsNo data available.10.4 Conditions to avoidNo data available.10.5 Incompatible materialsStrong acids/alkalis, strong oxidising/reducing agents.10.6 Hazardous decomposition productsUnder fire conditions, may decompose and emit toxic fumes.Other decomposition products - no data available.11.TOXICOLOGICAL INFORMATION11.1 Information on toxicological effectsAcute toxicityClassified based on available data. For more details, see section 2Skin corrosion/irritationClassified based on available data. For more details, see section 2Serious eye damage/irritationClassified based on available data. For more details, see section 2Respiratory or skin sensitizationClassified based on available data. For more details, see section 2Germ cell mutagenicityClassified based on available data. For more details, see section 2CarcinogenicityIARC: No component of this product present at a level equal to or greater than 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.ACGIH: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by ACGIH.NTP: No component of this product present at a level equal to or greater than 0.1% is identified as a anticipated or confirmed carcinogen by NTP.OSHA: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by OSHA.Reproductive toxicityClassified based on available data. For more details, see section 2Specific target organ toxicity - single exposureClassified based on available data. For more details, see section 2Specific target organ toxicity - repeated exposureClassified based on available data. For more details, see section 2Aspiration hazardClassified based on available data. For more details, see section 212. ECOLOGICAL INFORMATION12.1 ToxicityNo data available.12.2 Persistence and degradabilityNo data available.12.3 Bioaccumlative potentialNo data available.12.4 Mobility in soilNo data available.12.5 Results of PBT and vPvB assessmentPBT/vPvB assessment unavailable as chemical safety assessment not required or not conducted.12.6 Other adverse effectsNo data available.13. DISPOSAL CONSIDERATIONS13.1 Waste treatment methodsProductDispose substance in accordance with prevailing country, federal, state and local regulations.Contaminated packagingConduct recycling or disposal in accordance with prevailing country, federal, state and local regulations.14. TRANSPORT INFORMATIONDOT (US)This substance is considered to be non-hazardous for transport.IMDGThis substance is considered to be non-hazardous for transport.IATAThis substance is considered to be non-hazardous for transport.15. REGULATORY INFORMATIONSARA 302 Components:No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.SARA 313 Components:This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.SARA 311/312 Hazards:No SARA Hazards.Massachusetts Right To Know Components:No components are subject to the Massachusetts Right to Know Act.Pennsylvania Right To Know Components:No components are subject to the Pennsylvania Right to Know Act.New Jersey Right To Know Components:No components are subject to the New Jersey Right to Know Act.California Prop. 65 Components:This product does not contain any chemicals known to State of California to cause cancer, birth defects, or anyother reproductive harm.16. OTHER INFORMATIONCopyright 2017 MedChemExpress. The above information is correct to the best of our present knowledge but does not purport to be all inclusive and should be used only as a guide. The product is for research use only and for experienced personnel. It must only be handled by suitably qualified experienced scientists in appropriately equipped and authorized facilities. The burden of safe use of this material rests entirely with the user. MedChemExpress disclaims all liability for any damage resulting from handling or from contact with this product.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。
原发性醛固酮增多症(中英文
• 原醛症病人一般服用安体舒通1周后，尿 钾减少、血钾上升、血浆CO2结合力下 降，肌无力、四肢麻木等症状改善，夜 尿减少，约半数病人血压有下降趋势。
原醛的筛查
• 立，卧位的血ARR=ALDO/PRA。各种文 献对比值报道不一，>25可疑， > 50可能 性大。
• 如果同时运用下述标准:ALDO/PRA>30, ALDO>20ng/dl, 其诊断原醛的灵敏性为 90%，特异性为91% 。
原醛的确诊
FST
氟氢可的松0.1mg q6h，共4天 ➢测定立位ALDO>60pg/dl，立位PRA ＜1.0ng/ml ➢尿钠的排泄>3 mmol/kg/天 ➢血K正常。 ➢服药4天后10Am的血浆皮质醇必须低于7Am 的
皮质醇
盐负荷试验
• 静脉和口服 • 静脉：生理盐水2L，4小时内静注完，测
定血ALDO >5ng/dl，PA确诊。 • 口服：高钠饮食3天（300mmol钠/d），
测定24小时尿ALDO >10µg/d， PA确诊
盐负荷试验
• 高钠试验正常人及高血压病人血钾无明 显变化，原醛症患者血钾可降至3．5毫 摩尔/升以下
Schimenbach, Best Pract Res Clin Endocrinol Metab. 2006 Sep;20(3):369-84
机制
肾上腺皮质病变Aldo↑储NA排K 血容量↑ PRA↓
自主性
低K
BP↑
临床特点
1.BP↑ : 血容量↑,平滑肌内NA↑,Aldo增加血 管对NAR的反应. 最早最常见,病程进展, BP逐渐↑,轻中度.以DBP ↑为主 伴头晕,头痛.
type I) • FH type II (APA or IHA)
阿替洛尔(标准品)
中文品名阿替洛尔（标准品）
CAS 号29122-68-7
英文品名Atenolol
分子式：C14H22N2O3 分子量：266.34
检测条件：
方法：HPLC
流动相:…………………………………磷酸盐缓冲液-甲醇（70：30)
检测波长：…………………………….226nm
色谱柱:…………………………………十八烷基硅烷键合硅胶为填充剂
用途：对照标准品，用于分析对照，含量测定
阿替洛尔（标准品）的溶解性，阿替洛尔（标准品）在水中的溶解性，阿替洛尔（标准品）在生理盐水中的溶解性，阿替洛尔（标准品）在PBS缓冲液中的溶解性，阿替洛尔（标准品）在DMSO、乙醇等有机溶剂中的溶解性，阿替洛尔（标准品）在细胞实验方面的应用，阿替洛尔（标准品）在大鼠等动物实验方面的应用。
SNS-032_DataSheet_MedChemExpress
Inhibitors, Agonists, Screening Libraries Data SheetBIOLOGICAL ACTIVITY:SNS–032 is a selective inhibitor of cyclin–dependent kinase (CDK), inhibiting CDK2/7/9 with IC 50s of 48 nM/62 nM/4 nM.IC50 & Target: IC50: 48 nM (CDK2), 62 nM (CDK7), 4 nM (CDK9)In Vitro: SNS–032 has low sensitivity to CDK1 and CDK4 with IC 50 of 480 nM and 925 nM, respectively. SNS–032 effectively kills chronic lymphocytic leukemia cells in vitro regardless of prognostic indicators and treatment history. Compared with flavopiridol and roscovitine, SNS–032 is more potent, both in inhibition of RNA synthesis and at induction of apoptosis. SNS–032 activity is readily reversible; removal of SNS–032 reactivates RNA polymerase II, which led to resynthesis of Mcl–1 and cell survival [1].SNS–032 inhibits three dimensional capillary network formations of endothelial cells. SNS–032 completely prevents U87MGcell–mediated capillary formation of HUVECs. In addition, SNS–032 significantly prevents the production of VEGF in both cell lines,SNS–032 prevents in vitro angiogenesis, and this action is attributable to blocking of VEGF. Preclinical studies have shown that SNS–032 induces cell cycle arrest and apoptosis across multiple cell lines [2]. SNS–032 blocks the cell cycle via inhibition of CDKs 2and 7, and transcription via inhibition of CDKs 7 and 9. SNS–032 activity is unaffected by human serum [3]. SNS–032 induces a dose–dependent increase in annexin V staining and caspase–3 activation. At the molecular level, SNS–032 induces a marked dephosphorylation of serine 2 and 5 of RNA polymerase (RNA Pol) II and inhibits the expression of CDK2 and CDK9 anddephosphorylated CDK7[5].In Vivo: SNS–032 (15 mg/kg, i.p.) inhibits both xenografted BaF3–T674I cells and KBM5–T315I cells in vivo. SNS–032 abrogates the growth of tumors transplanted in nude mice with downregulation of T674I PDGFRα and T315I–Bcr–Abl [4].PROTOCOL (Extracted from published papers and Only for reference)Cell Assay:[2]Cell Titer–Glo (CTG) luminescent assay is performed to measure the growth curves of both HUVECs andU87MG cells. U87MG cells and HUVECs (2×103 cells/well) are seeded in a 96–well microplate in a final volume of 100 mL. After 24hours, cells are treated with various doses of SNS–032 (0–0.5 mM) for 24, 48, or 72 hours. After completion of the treatment, 100 mL of CTG solution is added to each well and incubated for 20 minutes at room temperature in the dark. Lysate (50 mL) is transferred to a 96–well white plate, and luminescence is measured by POLARstar OPTIMA. Percent cell growth is calculated by considering 100%growth at the time of SNS–032 addition.Animal Administration: SNS–032 is dissolved in tissue culture grade DMSO. [4]Nude nu/nu BALB/c mice are housed in barrier facilities with a 12–hour light–dark cycle, with food and water available ad libitum. A mixture of 1×107 of BaF3–T674I cells withMatrigel or KBM5–T315I cells (3×107) are inoculated subcutaneously on the flanks of 4– to 6–week–old male nude mice.Tumors are measured every other day with use of calipers. Tumor volumes are calculated by the following formula: a 2×b×0.4,where a is the smallest diameter and b is the diameter perpendicular to a. Four days after subcutaneous inoculation, when tumors are palpable (appr 100 mm 3), mice are randomized to receive treatment with vehicle (tissue culture medium containing DMSO 0.1%v/v) or SNS–032 (15 mg/kg injected intraperitoneally every 2 days) for about 2 weeks. SNS–032 is dissolved in tissue culture gradeProduct Name:SNS–032Cat. No.:HY-10008CAS No.:345627-80-7Molecular Formula:C 17H 24N 4O 2S 2Molecular Weight:380.53Target:CDK Pathway:Cell Cycle/DNA Damage Solubility:10 mM in DMSODMSO before dilution. The body weight, feeding behavior, and motor activity of each animal are monitored as indicators of general health. The animals are then euthanized, and tumor xenografts are immediately removed, weighed, stored, and fixed.References:[1]. Chen R, et al. Mechanism of action of SNS–032, a novel cyclin–dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2009 May 7;113(19):4637–45.[2]. Ali MA, et al. SNS–032 prevents tumor cell–induced angiogenesis by inhibiting vascular endothelial growth factor. Neoplasia. 2007 May;9(5):370–81.[3]. Conroy A, et al. SNS–032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples. Cancer Chemother Pharmacol. 2009 Sep;64(4):723–32.[4]. Wu Y, et al. Cyclin–dependent kinase 7/9 inhibitor SNS–032 abrogates FIP1–like–1 platelet–derived growth factor receptor α and bcr–abl oncogene addiction in malignant hematologic cells.Clin Cancer Res. 2012 Apr 1;18(7):1966–78. Epub 2012 Mar 23.[5]. Walsby E, et al. The cyclin–dependent kinase inhibitor SNS–032 has single agent activity in AML cells and is highly synergistic with cytarabine.Leukemia. 2011 Mar;25(3):411–9. Epub 2011 Jan 7.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。
CortisolELISA试剂盒说明书,大鼠ELISA酶联免疫试剂盒
CortisolELISA试剂盒说明书，大鼠ELISA酶联免疫试剂盒CortisolELISA试剂盒说明书，大鼠ELISA酶联免疫试剂盒供应商：上海乔羽生物有限公司ELISA kit specification:(1) specifications: 96T can be measured 90 samples, 5 standard holes, 1 blank holes(2) specifications: 48T can be measured 42 samples, 5 standard holes, 1 blank holesCortisolELISA试剂盒说明书，大鼠ELISA酶联免疫试剂盒Kit composition:Sealing film: 2 (48) / 2 (96)Specifications: 1 copiesSealing bag: 1Standard: 2700ng / L 0.5 * 0.5ml * 1 bottles, 1 bottles are stored in 2-8 ELISA package is board: 1 X 48 x 961 2-8 stored inSample dilution: 3ml * 1 ml * 1 bottles of 6 bottles are stored in 2-8Color agent: Liquid 3ml * 1 ml * 6 bottles of 1 bottles in 2-8Color reagent B Liquid 3ml * 1 ml * 1 bottle 6 bottles stored in 2-8 Termination solution: 3ml * 6ml * 1 bottles and 1 bottles are stored in 2-8Concentrated laundry liquid: (2 * 20) * 1 bottles (20ml * 30) * 1 bottles stored in 2-8elisa试剂盒价格，elisa试剂盒说明书，elisa检测试剂盒CortisolELISA试剂盒说明书，大鼠ELISA酶联免疫试剂盒注意事项：1．试剂盒从冷藏环境中取出应在室温平衡15-30分钟后方可使用，酶标包被板开封后如未用完，板条应装入密封袋中保存。
英汉药名关联词典O6
Oxitriptan〖药品通⽤名〗羟⾊氨酸〖所属类别〗中枢神经系统药物/抗精神失常药/抗躁狂抑郁症药/抗抑郁症药 Oxitriptyline〖药品通⽤名〗奥昔替林〖所属类别〗中枢神经系统药物/抗精神失常药/抗躁狂抑郁症药/抗抑郁症药 Oxitropium Bromide〖药品通⽤名〗氧托溴铵〖所属类别〗植物神经系统药物/抗胆碱药 Oxitropium Methylbromide〖药品通⽤名〗甲溴氧托铵〖所属类别〗植物神经系统药物/抗胆碱药 Oxmetidine〖药品通⽤名〗奥美替丁〖所属类别〗消化系统药物/抗酸药及治疗消化性溃疡病药 Oxodipine〖药品通⽤名〗奥索地平〖所属类别〗循环系统药物/降⾎压药 Oxogestone〖药品通⽤名〗奥索孕酮〖所属类别〗激素及有关药物/性激素及促性激素/孕激素类 Oxohydroxyoestrin〖英⽂通⽤名〗Estrone〖中⽂通⽤名〗雌酮〖所属类别〗激素及有关药物/性激素及促性激素/雌激素及类似合成药物 Oxolamin〖英⽂通⽤名〗Nicocodine〖中⽂通⽤名〗尼可待因〖所属类别〗呼吸系统药物/镇咳药 Oxolamine〖药品通⽤名〗奥索拉明〖所属类别〗呼吸系统药物/镇咳药 Oxolamine Citrate〖英⽂通⽤名〗Nicocodine〖中⽂通⽤名〗尼可待因〖所属类别〗呼吸系统药物/镇咳药 Oxolan〖药品通⽤名〗草脲胺〖所属类别〗呼吸系统药物/平喘药/其它类 Oxolinic Acid〖药品通⽤名〗奥索利酸〖所属类别〗抗微⽣物药物/合成抗菌药/喹诺酮类 Oxomemazine〖药品通⽤名〗奥索马嗪〖所属类别〗抗变态反应药物/抗组胺药 Oxophenarsine〖药品通⽤名〗氧芬胂〖所属类别〗抗微⽣物药物/抗⿇风病药及抗⿇风病反应药 Oxoprostol〖药品通⽤名〗氧前列醇〖所属类别〗消化系统药物/抗酸药及治疗消化性溃疡病药 Oxpentifylline〖英⽂通⽤名〗Pentoxifylline〖中⽂通⽤名〗⼰酮可可碱〖所属类别〗中枢神经系统药物/其它类 Oxpheneridine〖药品通⽤名〗羟芬利定〖所属类别〗中枢神经系统药物/镇痛药 Oxprenoate Potassium〖药品通⽤名〗奥孕酸钾 Oxprenolol〖药品通⽤名〗氧烯洛尔〖所属类别〗植物神经系统药物/抗肾上腺素药/β受体阻滞剂 Oxthoxine〖英⽂通⽤名〗Methoxyphenamine〖中⽂通⽤名〗甲氧那明〖所属类别〗呼吸系统药物/平喘药/β肾上腺素受体激动剂 Oxtriphylline〖英⽂通⽤名〗Choline Theophyllinate〖中⽂通⽤名〗胆茶碱〖所属类别〗呼吸系统药物/平喘药/磷酸⼆酯酶抑制剂 Oxtriphytline〖英⽂通⽤名〗Choline Theophyllinate〖中⽂通⽤名〗胆茶碱〖所属类别〗呼吸系统药物/平喘药/磷酸⼆酯酶抑制剂 Oxybenzone〖药品通⽤名〗羟苯甲酮〖所属类别〗各临床科室备⽤药物/⽪肤科⽤药 Oxybicycline〖英⽂通⽤名〗Oxytetracycline〖中⽂通⽤名〗⼟霉素〖所属类别〗抗微⽣物药物/抗⽣素/四环素类 Oxybrain〖药品商品名〗奥勃兰〖英⽂通⽤名〗Vincamine〖中⽂通⽤名〗长春胺 Oxybromonaftoicoic Acid〖药品通⽤名〗羟溴萘酸〖所属类别〗消化系统药物/肝胆疾病辅助⽤药/利胆药 Oxybuprocaine〖药品通⽤名〗奥布卡因〖所属类别〗⿇醉药及其辅助⽤药/局部⿇醉药 Oxybuprocaine Hydrochloride〖药品商品名〗新表灵〖英⽂通⽤名〗Oxybuprocaine〖中⽂通⽤名〗奥布卡因 Oxybutazone〖英⽂通⽤名〗Oxyphenbutazone〖中⽂通⽤名〗羟布宗〖所属类别〗中枢神经系统药物/解热镇痛抗炎及抗痛风药/解热镇痛药 Oxybutynin〖药品通⽤名〗奥昔布宁〖所属类别〗⿇醉药及其辅助⽤药/解痉药 Oxybutynin Chloride〖英⽂通⽤名〗Oxybutynin〖中⽂通⽤名〗奥昔布宁〖所属类别〗⿇醉药及其辅助⽤药/解痉药 Oxybutynine〖英⽂通⽤名〗Oxybutynin〖中⽂通⽤名〗奥昔布宁〖所属类别〗⿇醉药及其辅助⽤药/解痉药 Oxybutynin Hydrochloride Tablets〖药品商品名〗盐酸奥昔布宁⽚〖英⽂通⽤名〗Oxybutynin〖中⽂通⽤名〗奥昔布宁 Oxycel〖英⽂通⽤名〗Oxidized Cellulose〖中⽂通⽤名〗氧化纤维素〖所属类别〗影响⾎液及造⾎系统的药物/促凝⾎药 Oxycellulose〖英⽂通⽤名〗Oxidized Cellulose〖中⽂通⽤名〗氧化纤维素〖所属类别〗影响⾎液及造⾎系统的药物/促凝⾎药 Oxychloroquine〖英⽂通⽤名〗Hydroxychloroquine〖中⽂通⽤名〗羟氯喹〖所属类别〗抗寄⽣⾍病药物/抗疟药 Oxychlorosene〖药品通⽤名〗奥昔氯⽣〖所属类别〗各临床科室备⽤药物/外科⽤药及消毒防腐收敛药 Oxychlorpromazine〖药品通⽤名〗氧氯丙嗪〖所属类别〗中枢神经系统药物/抗精神失常药/抗精神病药 Oxycinchophen〖药品通⽤名〗羟⾟可芬〖所属类别〗中枢神经系统药物/解热镇痛抗炎及抗痛风药/抗炎镇痛药 Oxyclipine〖药品通⽤名〗奥昔利平〖所属类别〗植物神经系统药物/抗胆碱药 Oxyclipine Hydrochloride〖英⽂通⽤名〗Oxyclipine〖中⽂通⽤名〗奥昔利平〖所属类别〗植物神经系统药物/抗胆碱药 Oxyclozanide〖药品通⽤名〗羟氯扎胺〖所属类别〗抗寄⽣⾍病药物/抗其它吸⾍病药 Oxycodone〖药品通⽤名〗羟考酮〖所属类别〗中枢神经系统药物/镇痛药 Oxycontin〖药品商品名〗奥施康定〖英⽂通⽤名〗Oxycodone〖中⽂通⽤名〗羟考酮 Oxycoumarin〖药品通⽤名〗奥昔⾹⾖素〖所属类别〗影响⾎液及造⾎系统的药物/抗凝⾎药 Oxydipentonium Chloride〖药品通⽤名〗奥地氯铵〖所属类别〗⿇醉药及其辅助⽤药/⾻骼肌松弛药 Oxydum Nitrosum〖英⽂通⽤名〗Nitrous Oxide〖中⽂通⽤名〗氧化亚氮〖所属类别〗⿇醉药及其辅助⽤药/全⾝⿇醉药/吸⼊⿇醉药 Oxyfedrine〖药品通⽤名〗奥昔⾮君〖所属类别〗循环系统药物/防治⼼绞痛药 Oxyfedrine Hydrochloride〖英⽂通⽤名〗Oxyfedrine〖中⽂通⽤名〗奥昔⾮君〖所属类别〗循环系统药物/防治⼼绞痛药 Oxyfenamate〖药品通⽤名〗奥芬氨酯〖所属类别〗中枢神经系统药物/抗精神失常药/抗焦虑药 Oxyflavil〖英⽂通⽤名〗Efloxate〖中⽂通⽤名〗⼄氧黄酮〖所属类别〗循环系统药物/防治⼼绞痛药 Oxygen〖药品商品名〗氧 Oxylan〖英⽂通⽤名〗Phenytoin〖中⽂通⽤名〗苯妥英〖所属类别〗中枢神经系统药物/抗癫痫药 Oxylin〖药品商品名〗欧斯啉〖英⽂通⽤名〗Oxymetazoline〖中⽂通⽤名〗羟甲唑啉 Oxylone〖英⽂通⽤名〗Fluorometholone〖中⽂通⽤名〗氟⽶龙〖所属类别〗激素及有关药物/肾上腺⽪质激素及促肾上腺⽪质激素 Oxylycorium Acetate〖药品通⽤名〗⽯蒜醋铵〖所属类别〗抗肿瘤药物/其它抗肿瘤药及辅助治疗药 Oxymesterone〖药品通⽤名〗羟甲睾酮〖所属类别〗激素及有关药物/性激素及促性激素/雄激素及同化激素 Oxymetazoline〖药品通⽤名〗羟甲唑啉〖所属类别〗抗变态反应药物/其它类 Oxymetazoline Hydrochloride Eye Drops〖药品商品名〗盐酸羟甲唑啉滴眼液〖英⽂通⽤名〗Oxymetazoline〖中⽂通⽤名〗羟甲唑啉 Oxymetazoline Hydrochloride Nasal Solution〖药品商品名〗盐酸羟甲唑啉滴⿐液〖英⽂通⽤名〗Oxymetazoline〖中⽂通⽤名〗羟甲唑啉 Oxymetazoline Hydrochloride Spray〖药品商品名〗盐酸羟甲唑啉喷雾剂〖英⽂通⽤名〗Oxymetazoline〖中⽂通⽤名〗羟甲唑啉 Oxymethebanol〖英⽂通⽤名〗Drotebanol〖中⽂通⽤名〗羟蒂巴酚〖所属类别〗呼吸系统药物/镇咳药 Oxymetholone〖药品通⽤名〗羟甲烯龙〖所属类别〗激素及有关药物/性激素及促性激素/雄激素及同化激素 Oxymethurea〖药品通⽤名〗双羟甲脲〖所属类别〗各临床科室备⽤药物/外科⽤药及消毒防腐收敛药 Oxymethylnicotinamid〖英⽂通⽤名〗Nicotinylmethylamide〖中⽂通⽤名〗羟甲烟胺〖所属类别〗消化系统药物/肝胆疾病辅助⽤药/利胆药 Oxymorphone〖药品通⽤名〗羟吗啡酮〖所属类别〗中枢神经系统药物/镇痛药 Oxymycin〖英⽂通⽤名〗Oxytetracycline〖中⽂通⽤名〗⼟霉素〖所属类别〗抗微⽣物药物/抗⽣素/四环素类 Oxynarin〖英⽂通⽤名〗Methoxyphenamine〖中⽂通⽤名〗甲氧那明〖所属类别〗呼吸系统药物/平喘药/β肾上腺素受体激动剂 Oxypendyl〖药品通⽤名〗奥昔喷地〖所属类别〗消化系统药物/⽌吐药、催吐药及肠胃推动药 Oxypertine〖药品通⽤名〗奥昔哌汀〖所属类别〗中枢神经系统药物/抗精神失常药/抗精神病药 Oxyphenbutazone〖药品通⽤名〗羟布宗〖所属类别〗中枢神经系统药物/解热镇痛抗炎及抗痛风药/解热镇痛药 Oxyphencyclimine〖药品通⽤名〗羟苄利明〖所属类别〗植物神经系统药物/抗胆碱药 Oxyphencyclimine Hydrochloride〖英⽂通⽤名〗Oxyphencyclimine〖中⽂通⽤名〗羟苄利明〖所属类别〗植物神经系统药物/抗胆碱药 Oxyphenisatin〖药品通⽤名〗酚丁〖所属类别〗消化系统药物/泻药 Oxyphenisatin Acetate〖药品通⽤名〗双醋酚丁〖所属类别〗消化系统药物/泻药 Oxyphenone〖英⽂通⽤名〗Oxyphenonium Bromide〖中⽂通⽤名〗奥芬溴铵〖所属类别〗植物神经系统药物/抗胆碱药 Oxyphenonium Bromide〖药品通⽤名〗奥芬溴铵〖所属类别〗植物神经系统药物/抗胆碱药 Oxypinocamphone〖药品通⽤名〗羟平酮〖所属类别〗呼吸系统药物/平喘药/其它类 Oxypyrronium Bromide〖药品通⽤名〗羟吡溴铵〖所属类别〗植物神经系统药物/抗胆碱药 Oxyquinoline〖药品通⽤名〗羟喹啉〖所属类别〗抗寄⽣⾍病药物/抗阿⽶巴病药 Oxysonium Iodide〖药品通⽤名〗奥昔碘锍〖所属类别〗植物神经系统药物/抗胆碱药 Oxytefonium〖英⽂通⽤名〗Oxitefonium Bromide〖中⽂通⽤名〗奥封溴铵〖所属类别〗植物神经系统药物/抗胆碱药 Oxyterracycline〖英⽂通⽤名〗Oxytetracycline〖中⽂通⽤名〗⼟霉素〖所属类别〗抗微⽣物药物/抗⽣素/四环素类 Oxytetracycline〖药品通⽤名〗⼟霉素〖所属类别〗抗微⽣物药物/抗⽣素/四环素类 Oxytetracycline Capsules〖药品商品名〗⼟霉素胶囊〖英⽂通⽤名〗Oxytetracycline〖中⽂通⽤名〗⼟霉素 Oxytetracycline Eye Ointment〖药品商品名〗⼟霉素眼膏〖英⽂通⽤名〗Oxytetracycline〖中⽂通⽤名〗⼟霉素 Oxytetracycline Ointment〖药品商品名〗⼟霉素软膏〖英⽂通⽤名〗Oxytetracycline〖中⽂通⽤名〗⼟霉素 Oxythiospasmin〖英⽂通⽤名〗Oxysonium Iodide〖中⽂通⽤名〗奥昔碘锍〖所属类别〗植物神经系统药物/抗胆碱药 Oxytocin〖药品通⽤名〗缩宫素〖所属类别〗⽣殖系统药物及泌乳功能药物/⼦宫收缩药及引产药 Oxytocin for Injection〖药品商品名〗注射⽤缩宫素〖英⽂通⽤名〗Oxytocin〖中⽂通⽤名〗缩宫素 Oxytocinum〖英⽂通⽤名〗Oxytocin〖中⽂通⽤名〗缩宫素〖所属类别〗⽣殖系统药物及泌乳功能药物/⼦宫收缩药及引产药 Oyster Shell〖中⽂名〗牡蛎〖拼⾳〗Muli〖拉丁名〗Concha Ostreae Ozagrel〖药品通⽤名〗奥扎格雷〖所属类别〗影响⾎液及造⾎系统的药物/抗⾎⼩板药物 Ozagrel Sodium-Bikai〖药品商品名〗晴尔〖英⽂通⽤名〗Ozagrel〖中⽂通⽤名〗奥扎格雷 Ozohine〖药品商品名〗奥苏芬〖英⽂通⽤名〗Diprophylline〖中⽂通⽤名〗⼆羟丙茶碱 Ozolinone〖药品通⽤名〗奥唑林酮〖所属类别〗泌尿系统药物/利尿药及脱⽔药/利尿药/其它类。